Modulation of thyroid hormone nuclear receptors by short-chain fatty acids in glial C6 cells. Role of histone acetylation.
We have studied the effect of butyrate and other short-chain fatty acids on thyroid hormone nuclear receptors in C6 cells, a rat glioma cell line. Exposure of C6 cells to butyrate leads to increased levels of L-triiodothyronine (T3) in the nuclear and extranuclear compartments. The rise in nuclear binding is not merely a reflection of the higher cellular hormone content, and Scatchard analysis of T3 binding to isolated nuclei reveals that butyrate increases receptor number without changing affinity. The effect on the receptor is quantitatively important: a 48-h incubation with 2 mM butyrate increases nuclear binding by 2-3-fold, and 5 mM butyrate by 3-5-fold. Other short-chain fatty acids were found to similarly influence both nuclear receptor and extranuclear T3 levels with the following potency: butyrate greater than valerate greater than propionate greater than acetate. On the contrary, ketone bodies were ineffective. Butyrate increases receptor levels by decreasing receptor degradation, since the apparent t1/2 of receptor disappearance increased by approximately 3-fold in cells incubated with 2 mM butyrate for 48 h. The regulation of receptor number might be secondary to an action of butyrate on regions of the chromatin to which the receptor associates. We then examined the effect of butyrate on histone acetylation. The fatty acid had little effect in increasing the level of multiacetylated forms of H3 and H4 histone when studied in acid-urea gels, but it markedly inhibited the turnover of [3H] acetate from the histone fraction. There was a striking similarity in the dose-response of butyrate for increasing receptor levels and inhibiting histone deacetylation. Furthermore, a very close correlation between receptor levels and [3H]acetate release was also found when different short-chain fatty acids were used. We thus conclude that the effect of butyrate on the receptor could be explained by a modification of the chromatin structure of C6 cells secondary to acetylation.
D000085:Acetates / Q000494:pharmacology; D019342:Acetic Acid; D000107:Acetylation; D000818:Animals; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002451:Cell Compartmentation; D002467:Cell Nucleus / Q000378:metabolism; D005227:Fatty Acids / Q000494:pharmacology*; D005910:Glioma / Q000378:metabolism; D006207:Half-Life; D006657:Histones / Q000378:metabolism*; D007657:Ketone Bodies / Q000494:pharmacology; D007700:Kinetics; D009457:Neuroglia / Q000378:metabolism*; D010421:Pentanoic Acids / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D011988:Receptors, Thyroid Hormone / Q000378:metabolism*; D013997:Time Factors; D014284:Triiodothyronine / Q000378:metabolism
D000085:Acetates; D002087:Butyrates; D005227:Fatty Acids; D006657:Histones; D007657:Ketone Bodies; D010421:Pentanoic Acids; D011422:Propionates; D011988:Receptors, Thyroid Hormone; D014284:Triiodothyronine; D020148:Butyric Acid; C038780:n-pentanoic acid; C029658:propionic acid; D019342:Acetic Acid